Suppr超能文献

在大流行中心进行肺癌手术的安全性。

Safety of lung cancer surgery during COVID-19 in a pandemic epicenter.

机构信息

Department of Cardiothoracic Surgery, Weill Cornell Medical Center/New York Presbyterian Hospital, New York, NY.

Department of Cardiothoracic Surgery, Weill Cornell Medical Center/New York Presbyterian Hospital, New York, NY.

出版信息

J Thorac Cardiovasc Surg. 2022 Aug;164(2):378-385. doi: 10.1016/j.jtcvs.2021.11.092. Epub 2022 Mar 1.

Abstract

BACKGROUND

The influence of SARS-CoV-2 on surgery for non-small cell lung cancer needs to be understood to inform clinical decision making during and after the COVID-19 pandemic.

OBJECTIVE

This study reports on the 90-day rate of infection as well as the morbidity and mortality of lung surgery for cancer in a tertiary care hospital located in a pandemic epicenter.

METHODS

We conducted a retrospective review of a prospective database to identify consecutive patients who underwent lung cancer resection before (January 1, 2020-March 10, 2020, group 1; 57 patients) and during the COVID-19 pandemic (March 11, 2020-June 10, 2020, group 2; 41 patients). The primary end point was the occurrence of SARS-CoV-2 infection during the first 90-days after surgery. The secondary outcome measure was 90-day perioperative morbidity and mortality.

RESULTS

Patient characteristics were not significantly different between the groups. Ninety-day COVID-19 infection rates was 7.3% (3 out of 41) for patients undergoing an operation during the pandemic and 3.5% (2 out of 57) in patients operated on immediately before the pandemic. All patients tested positive 10 to 62 days after the index surgical procedure following hospital discharge. Four COVID-19-positive patients were symptomatic and 4 out of 5 patients required hospitalization, were men, previous or current smokers with hyperlipidemia, and underwent a sublobar resection. Univariate analysis did not identify any differences in postoperative complications before or during the COVID-19 pandemic. Ninety-day mortality was 5% (2 out of 41) for lung cancer surgery performed during the pandemic, with all deaths occurring due to COVID-19, compared with 0% (0 out of 57) mortality in patients who underwent an operation before the pandemic.

CONCLUSIONS

During the COVID-19 pandemic, COVID-19 infections occurred in 7.3% of patients who underwent surgery for non-small cell lung cancer. In this series all infections occurred after hospital discharge. Our results suggest that COVID-19 infections occurring within 90 days of surgery portend a 40% mortality, warranting close postoperative surveillance.

摘要

背景

需要了解 SARS-CoV-2 对非小细胞肺癌手术的影响,以便在 COVID-19 大流行期间和之后为临床决策提供信息。

目的

本研究报告了一家位于大流行中心的三级保健医院中癌症肺手术的 90 天感染率以及发病率和死亡率。

方法

我们对一个前瞻性数据库进行了回顾性研究,以确定在 COVID-19 大流行之前(2020 年 1 月 1 日至 3 月 10 日,第 1 组;57 例患者)和期间(2020 年 3 月 11 日至 6 月 10 日,第 2 组;41 例患者)进行肺肿瘤切除术的连续患者。主要终点是手术后 90 天内发生 SARS-CoV-2 感染。次要结果测量是 90 天围手术期发病率和死亡率。

结果

两组患者的特征无明显差异。在大流行期间接受手术的患者中,90 天 COVID-19 感染率为 7.3%(41 例中有 3 例),而在大流行前立即接受手术的患者中为 3.5%(57 例中有 2 例)。所有患者在出院后 10 至 62 天进行了医院检测,结果均为阳性。4 名 COVID-19 阳性患者有症状,其中 4 名患者需要住院治疗,为男性,有或有吸烟史,有高血脂,行亚肺叶切除术。单变量分析未发现 COVID-19 大流行前后术后并发症的任何差异。在大流行期间进行的肺癌手术 90 天死亡率为 5%(41 例中有 2 例),所有死亡均归因于 COVID-19,而在大流行前接受手术的患者中死亡率为 0%(57 例中有 0 例)。

结论

在 COVID-19 大流行期间,有 7.3%的非小细胞肺癌手术患者发生 COVID-19 感染。在本系列中,所有感染均发生在出院后。我们的结果表明,手术后 90 天内发生的 COVID-19 感染预示着 40%的死亡率,需要密切的术后监测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddbe/8885108/1800eebb370b/fx1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验